Lv24
200 积分 2024-10-25 加入
Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics
13天前
已完结
Site of venous thromboembolism and prothrombotic mutations according to body mass index. Results from the EDITH study
13天前
已完结
Quantitative analysis of the CD4 T‐cell repertoire specific to therapeutic antibodies in healthy donors
13天前
已完结
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
13天前
已完结
In Vitro Immunogenicity Prediction: Bridging between Innate and Adaptive Immunity
13天前
已完结
In Vitro Immunogenicity Prediction: Bridging between Innate and Adaptive Immunity
13天前
已关闭
Clinical Impacts of Immunogenicity in Approved Antibody Drugs in Japan: A Quantitative Evaluation of Pharmacokinetics, Efficacy, and Safety Outcomes
16天前
已完结
Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays
1个月前
已完结
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform
1个月前
已完结
Applying MAPPs Assays to Assess Drug Immunogenicity
1个月前
已完结
皖公网安备34019202002308
